Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1912

1.

Tracheal Size and Morphology on the Reconstructed CT Imaging.

Mizuguchi S, Motomura Y, Maki J, Baba R, Ichimiya Y, Tokuda K, Kaku N, Takada H, Maehara Y, Ohga S.

Pediatr Crit Care Med. 2019 May 31. doi: 10.1097/PCC.0000000000001996. [Epub ahead of print]

PMID:
31162371
2.

Cytotoxicity of trifluridine correlates with the thymidine kinase 1 expression level.

Kataoka Y, Iimori M, Niimi S, Tsukihara H, Wakasa T, Saeki H, Oki E, Maehara Y, Kitao H.

Sci Rep. 2019 May 28;9(1):7964. doi: 10.1038/s41598-019-44399-6.

3.

Late-onset sepsis and encephalopathy after bicycle-spoke injury: a case report.

Takemoto R, Motomura Y, Kaku N, Ichimiya Y, Muraoka M, Kanno S, Tanaka T, Sakai Y, Maehara Y, Ohga S.

BMC Infect Dis. 2019 May 28;19(1):472. doi: 10.1186/s12879-019-4082-4.

4.

Prognosis of Early-stage Part-solid and Pure-solid Lung Adenocarcinomas.

Kinoshita F, Toyokawa G, Matsubara T, Kozuma Y, Haratake N, Takamori S, Akamine T, Hirai F, Takenaka T, Tagawa T, Maehara Y.

Anticancer Res. 2019 May;39(5):2665-2670. doi: 10.21873/anticanres.13391.

PMID:
31092466
5.

Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A).

Sasaki S, Oki E, Saeki H, Shimose T, Sakamoto S, Hu Q, Kudo K, Tsuda Y, Nakashima Y, Ando K, Akagi Y, Kakeji Y, Baba H, Maehara Y.

Int J Clin Oncol. 2019 May 6. doi: 10.1007/s10147-019-01460-8. [Epub ahead of print]

PMID:
31062115
6.

Efficacy of Novel Multispectral Imaging Device to Determine Anastomosis for Esophagogastrostomy.

Tsutsumi R, Ikeda T, Nagahara H, Saeki H, Nakashima Y, Oki E, Maehara Y, Hashizume M.

J Surg Res. 2019 May 3;242:11-22. doi: 10.1016/j.jss.2019.04.033. [Epub ahead of print]

7.

A novel prognostic marker in patients with non-small cell lung cancer: musculo-immuno-nutritional score calculated by controlling nutritional status and creatine kinase.

Takamori S, Toyokawa G, Shimokawa M, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Hirai F, Tagawa T, Oda Y, Maehara Y.

J Thorac Dis. 2019 Mar;11(3):927-935. doi: 10.21037/jtd.2019.01.76.

8.

Bone morphogenetic protein 4 provides cancer-supportive phenotypes to liver fibroblasts in patients with hepatocellular carcinoma.

Mano Y, Yoshio S, Shoji H, Tomonari S, Aoki Y, Aoyanagi N, Okamoto T, Matsuura Y, Osawa Y, Kimura K, Yugawa K, Wang H, Oda Y, Yoshizumi T, Maehara Y, Kanto T.

J Gastroenterol. 2019 Apr 2. doi: 10.1007/s00535-019-01579-5. [Epub ahead of print]

PMID:
30941514
9.

IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.

Imai D, Yoshizumi T, Okano S, Itoh S, Ikegami T, Harada N, Aishima S, Oda Y, Maehara Y.

J Surg Res. 2019 Aug;240:115-123. doi: 10.1016/j.jss.2019.02.038. Epub 2019 Mar 27.

PMID:
30927618
10.

[A Study of the Usefulness of Decompression in Treating Bowel Obstruction Due to Colorectal Cancer].

Higashi T, Ikeda Y, Nobutou Y, Ohgaki K, Kinjou N, Maehara S, Nakamura T, Teramoto S, Saito G, Adachi E, Kounoe S, Maehara Y.

Gan To Kagaku Ryoho. 2019 Feb;46(2):318-320. Japanese.

PMID:
30914546
11.

External validation of CLI Frailty Index and assessment of predictive value of modified CLI Frailty Index for patients with critical limb ischemia undergoing infrainguinal revascularization.

Morisaki K, Furuyama T, Matsubara Y, Inoue K, Kurose S, Yoshino S, Nakayama K, Yamashita S, Yoshiya K, Yoshiga R, Maehara Y.

Vascular. 2019 Mar 19:1708538119836005. doi: 10.1177/1708538119836005. [Epub ahead of print]

PMID:
30890090
12.

Tumor suppressor KIF1Bβ regulates mitochondrial apoptosis in collaboration with YME1L1.

Ando K, Yokochi T, Mukai A, Wei G, Li Y, Kramer S, Ozaki T, Maehara Y, Nakagawara A.

Mol Carcinog. 2019 Jul;58(7):1134-1144. doi: 10.1002/mc.22997. Epub 2019 Mar 11.

PMID:
30859632
13.

Short- and Long-term Outcomes of Surgical Treatment for Remnant Gastric Cancer After Distal Gastrectomy.

Nakaji YU, Saeki H, Kudou K, Nakanishi R, Sugiyama M, Nakashima Y, Ando K, Oda Y, Oki E, Maehara Y.

Anticancer Res. 2019 Mar;39(3):1411-1415. doi: 10.21873/anticanres.13256.

PMID:
30842176
14.

Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study.

Tomita N, Kunieda K, Maeda A, Hamada C, Yamanaka T, Sato T, Yoshida K, Boku N, Nezu R, Yamaguchi S, Mishima H, Sadahiro S, Muro K, Ishiguro M, Sakamoto J, Saji S, Maehara Y.

Br J Cancer. 2019 Apr;120(7):689-696. doi: 10.1038/s41416-019-0410-0. Epub 2019 Mar 5.

PMID:
30833647
15.

A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.

Matsubara T, Takada K, Azuma K, Takamori S, Toyokawa G, Haro A, Osoegawa A, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

Ann Surg Oncol. 2019 Jun;26(6):1925-1933. doi: 10.1245/s10434-019-07257-3. Epub 2019 Feb 27.

PMID:
30815803
16.

Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients.

Takamori S, Takada K, Azuma K, Jogo T, Shimokawa M, Toyokawa G, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

Ann Surg Oncol. 2019 Jun;26(6):1916-1924. doi: 10.1245/s10434-019-07231-z. Epub 2019 Feb 27.

PMID:
30815801
17.

Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation: a Japanese multicenter experience.

Ueda Y, Kobayashi T, Ikegami T, Miuma S, Mizuno S, Akamatsu N, Takaki A, Ishigami M, Takatsuki M, Sugawara Y, Maehara Y, Uemoto S, Seno H.

J Gastroenterol. 2019 Jul;54(7):660-666. doi: 10.1007/s00535-019-01561-1. Epub 2019 Feb 26.

PMID:
30806783
18.

Daikenchuto accelerates the recovery from prolonged postoperative ileus after open abdominal surgery: a subgroup analysis of three randomized controlled trials.

Kono T, Shimada M, Nishi M, Morine Y, Yoshikawa K, Katsuno H, Maeda K, Koeda K, Morita S, Watanabe M, Kusano M, Sakamoto J, Saji S, Sokuoka H, Sato Y, Maehara Y, Kanematsu T, Kitajima M.

Surg Today. 2019 Feb 25. doi: 10.1007/s00595-019-01787-9. [Epub ahead of print]

PMID:
30805720
19.

The Significance of CD44 Variant 9 in Resected Lung Adenocarcinoma: Correlation with Pathological Early-Stage and EGFR Mutation.

Akamine T, Tagawa T, Ijichi K, Toyokawa G, Takamori S, Hirai F, Okamoto T, Oda Y, Maehara Y.

Ann Surg Oncol. 2019 May;26(5):1544-1551. doi: 10.1245/s10434-018-07137-2. Epub 2019 Feb 24.

PMID:
30798450
20.

Successful Bridge Therapy with Initial Endovascular Repair for Arterioenteric Fistula Resulting from Pseudoaneurysm Rupture with Massive Gastrointestinal Hemorrhage after Pancreas Transplantation.

Kurose S, Inoue K, Yoshino S, Nakayama K, Yamashita S, Yoshiya K, Yoshiga R, Morisaki K, Kaku K, Okabe Y, Furuyama T, Maehara Y.

Ann Vasc Surg. 2019 Jul;58:379.e15-379.e22. doi: 10.1016/j.avsg.2018.10.028. Epub 2019 Jan 31.

PMID:
30711503
21.

Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes in patients with breast cancer.

Shibata T, Tokunaga E, Hattori S, Watari K, Murakami Y, Yamashita N, Oki E, Itou J, Toi M, Maehara Y, Kuwano M, Ono M.

Oncotarget. 2018 Dec 14;9(98):37216-37228. doi: 10.18632/oncotarget.26469. eCollection 2018 Dec 14.

22.

POGLUT1, the putative effector gene driven by rs2293370 in primary biliary cholangitis susceptibility locus chromosome 3q13.33.

Hitomi Y, Ueno K, Kawai Y, Nishida N, Kojima K, Kawashima M, Aiba Y, Nakamura H, Kouno H, Kouno H, Ohta H, Sugi K, Nikami T, Yamashita T, Katsushima S, Komeda T, Ario K, Naganuma A, Shimada M, Hirashima N, Yoshizawa K, Makita F, Furuta K, Kikuchi M, Naeshiro N, Takahashi H, Mano Y, Yamashita H, Matsushita K, Tsunematsu S, Yabuuchi I, Nishimura H, Shimada Y, Yamauchi K, Komatsu T, Sugimoto R, Sakai H, Mita E, Koda M, Nakamura Y, Kamitsukasa H, Sato T, Nakamuta M, Masaki N, Takikawa H, Tanaka A, Ohira H, Zeniya M, Abe M, Kaneko S, Honda M, Arai K, Arinaga-Hino T, Hashimoto E, Taniai M, Umemura T, Joshita S, Nakao K, Ichikawa T, Shibata H, Takaki A, Yamagiwa S, Seike M, Sakisaka S, Takeyama Y, Harada M, Senju M, Yokosuka O, Kanda T, Ueno Y, Ebinuma H, Himoto T, Murata K, Shimoda S, Nagaoka S, Abiru S, Komori A, Migita K, Ito M, Yatsuhashi H, Maehara Y, Uemoto S, Kokudo N, Nagasaki M, Tokunaga K, Nakamura M.

Sci Rep. 2019 Jan 14;9(1):102. doi: 10.1038/s41598-018-36490-1.

23.

Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.

Takada K, Kohashi K, Shimokawa M, Haro A, Osoegawa A, Tagawa T, Seto T, Oda Y, Maehara Y.

Lung Cancer. 2019 Feb;128:26-32. doi: 10.1016/j.lungcan.2018.12.008. Epub 2018 Dec 10.

PMID:
30642449
24.

Primary amelanotic malignant melanoma of the esophagus: a case report.

Koga N, Kubo N, Saeki H, Sasaki S, Jogo T, Hirose K, Nakashima Y, Oki E, Koga Y, Oda Y, Oiwa H, Oiwa T, Maehara Y.

Surg Case Rep. 2019 Jan 11;5(1):4. doi: 10.1186/s40792-019-0564-2.

25.

The prognostic impact of obstructive lung disease on survival of never smokers with resected non-small-cell lung cancer: a comparison with smokers.

Akamine T, Tagawa T, Shimokawa M, Matsubara T, Kozuma Y, Haratake N, Takamori S, Toyokawa G, Maehara Y.

Interact Cardiovasc Thorac Surg. 2019 Jan 2. doi: 10.1093/icvts/ivy329. [Epub ahead of print]

PMID:
30602039
26.

Functional Analysis of Human Hepatocytes Isolated From Chimeric Mouse Liver.

Harimoto N, Nakagawara H, Shirabe K, Yoshizumi T, Itoh S, Ikegami T, Soejima Y, Maehara Y, Ishida Y, Tateno C, Tanaka Y.

Transplant Proc. 2018 Dec;50(10):3858-3862. doi: 10.1016/j.transproceed.2018.06.035. Epub 2018 Jun 30.

PMID:
30577278
27.

Real-Time Ultrasound-Guided Thrombectomy for Extensive Portal Vein Thrombosis in Living Donor Liver Transplantation.

Soejima Y, Yoshizumi T, Ikegami T, Harimoto N, Harada N, Itoh S, Toshima T, Motomura T, Mano Y, Ohira M, Bekki Y, Maehara Y.

Transplant Proc. 2018 Dec;50(10):3549-3551. doi: 10.1016/j.transproceed.2018.08.047. Epub 2018 Sep 6.

PMID:
30577235
28.

HMGB1 blockade significantly improves luminal fibrous obliteration in a murine model of bronchiolitis obliterans syndrome.

Takamori S, Shoji F, Okamoto T, Kozuma Y, Matsubara T, Haratake N, Akamine T, Katsura M, Takada K, Toyokawa G, Tagawa T, Maehara Y.

Transpl Immunol. 2019 Apr;53:13-20. doi: 10.1016/j.trim.2018.11.007. Epub 2018 Dec 1.

PMID:
30508580
29.

Neoadjuvant Chemotherapy Versus Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma.

Nakashima Y, Saeki H, Hu Q, Tsuda Y, Hisamatsu Y, Ando K, Oki E, Maehara Y.

Anticancer Res. 2018 Dec;38(12):6809-6814. doi: 10.21873/anticanres.13053.

PMID:
30504394
30.

Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer.

Hashimoto D, Arima K, Nakagawa S, Negoro Y, Hirata T, Hirota M, Inomata M, Fukuzawa K, Ohga T, Saeki H, Oki E, Yamashita YI, Chikamoto A, Baba H, Maehara Y.

J Gastroenterol. 2019 May;54(5):437-448. doi: 10.1007/s00535-018-01535-9. Epub 2018 Dec 4.

PMID:
30515563
31.

Postoperative Skeletal Muscle Loss Predicts Poor Prognosis of Adenocarcinoma of Upper Stomach and Esophagogastric Junction.

Kudou K, Saeki H, Nakashima Y, Kimura K, Ando K, Oki E, Ikeda T, Maehara Y.

World J Surg. 2019 Apr;43(4):1068-1075. doi: 10.1007/s00268-018-4873-6.

PMID:
30478682
32.

CD44v9 is associated with epithelial-mesenchymal transition and poor outcomes in esophageal squamous cell carcinoma.

Taniguchi D, Saeki H, Nakashima Y, Kudou K, Nakanishi R, Kubo N, Ando K, Oki E, Oda Y, Maehara Y.

Cancer Med. 2018 Dec;7(12):6258-6268. doi: 10.1002/cam4.1874. Epub 2018 Nov 26.

33.

Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors.

Takamori S, Takada K, Tagawa T, Toyokawa G, Hirai F, Yamashita N, Okamoto T, Oki E, Yoshizumi T, Oda Y, Maehara Y.

Surg Oncol. 2018 Dec;27(4):637-641. doi: 10.1016/j.suronc.2018.08.001. Epub 2018 Aug 11.

PMID:
30449485
34.

Impact of Osteopenia in Liver Cirrhosis: Special Reference to Standard Bone Mineral Density with Age.

Toshima T, Yoshizumi T, Ikegami T, Harada N, Itoh S, Mano Y, Motomura T, Soejima Y, Maehara Y.

Anticancer Res. 2018 Nov;38(11):6465-6471. doi: 10.21873/anticanres.13009.

PMID:
30396973
35.

BUBR1 Insufficiency Is Correlated with eNOS Reduction Experimentally In Vitro and In Vivo, and in Gastric Cancer Tissue.

Kawakubo E, Matsumoto T, Yoshiya K, Yamashita S, Jogo T, Saeki H, Oki E, Furuyama T, Oda Y, Maehara Y.

Anticancer Res. 2018 Nov;38(11):6099-6106. doi: 10.21873/anticanres.12960.

PMID:
30396924
36.

Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).

Saeki H, Oki E, Kashiwada T, Arigami T, Makiyama A, Iwatsuki M, Narita Y, Satake H, Matsuda Y, Sonoda H, Shimokawa M, Maehara Y; Kyushu Study Group of Clinical Cancer (KSCC).

Eur J Cancer. 2018 Dec;105:41-49. doi: 10.1016/j.ejca.2018.09.024. Epub 2018 Nov 2.

PMID:
30391779
37.

Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study.

Takada K, Toyokawa G, Azuma K, Takamori S, Jogo T, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

In Vivo. 2018 Nov-Dec;32(6):1541-1550. doi: 10.21873/invivo.11412.

38.

Changes in HER2 Expression and Amplification Status Following Preoperative Chemotherapy for Gastric Cancer.

Shu S, Iimori M, Nakanishi R, Jogo T, Saeki H, Oki E, Maehara Y.

In Vivo. 2018 Nov-Dec;32(6):1491-1498. doi: 10.21873/invivo.11405.

39.

A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas.

Toyokawa G, Takada K, Tagawa T, Hamamoto R, Yamada Y, Shimokawa M, Oda Y, Maehara Y.

Ann Thorac Surg. 2019 Feb;107(2):393-400. doi: 10.1016/j.athoracsur.2018.08.056. Epub 2018 Oct 18.

PMID:
30343006
40.

Effect of lateral lymph node dissection for mid and low rectal cancer: An ad-hoc analysis of the ACTS-RC (JFMC35-C1) randomized clinical trial.

Oki E, Shimokawa M, Ando K, Murata A, Takahashi T, Maeda K, Kusumoto T, Munemoto Y, Nakanishi R, Nakashima Y, Saeki H, Maehara Y.

Surgery. 2019 Mar;165(3):586-592. doi: 10.1016/j.surg.2018.08.027. Epub 2018 Oct 9.

PMID:
30314724
41.

Slow Gait Speed Is a Risk Factor for Complications After Hepatic Resection.

Itoh S, Yoshizumi T, Sakata K, Motomura T, Mano Y, Toshima T, Harimoto N, Harada N, Ikegami T, Soejima Y, Kusaba R, Kamishima T, Nishie A, Maehara Y.

J Gastrointest Surg. 2018 Oct 8. doi: 10.1007/s11605-018-3993-5. [Epub ahead of print]

PMID:
30298420
42.

Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer.

Takamori S, Takada K, Azuma K, Jogo Y, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Toyokawa G, Hirai F, Tagawa T, Okamoto I, Nakanishi Y, Kawahara A, Akiba J, Oda Y, Maehara Y.

Anticancer Res. 2018 Oct;38(10):5903-5907. doi: 10.21873/anticanres.12934.

PMID:
30275217
43.

PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer.

Takamori S, Takada K, Toyokawa G, Azuma K, Shimokawa M, Jogo T, Yamada Y, Hirai F, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.

Anticancer Res. 2018 Oct;38(10):5897-5901. doi: 10.21873/anticanres.12933.

PMID:
30275216
44.

miR-3148 Is a Novel Onco-microRNA that Potentiates Tumor Growth In Vivo.

Akamine T, Morodomi Y, Harada Y, Teraishi K, Tagawa T, Okamoto T, Maehara Y, Yonemitsu Y.

Anticancer Res. 2018 Oct;38(10):5693-5701. doi: 10.21873/anticanres.12906.

PMID:
30275189
45.

A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.

Okamoto T, Yano T, Shimokawa M, Takeo S, Yamazaki K, Sugio K, Takenoyama M, Nagashima A, Tsukamoto S, Hamatake M, Yokoyama H, Ueda H, Motohiro A, Tagawa T, Shoji F, Kometani T, Saito G, Fukuyama Y, Toyokawa G, Osoegawa A, Emi Y, Maehara Y; Kyushu University Lung Surgery Study Group (KLSS) Japan.

Lung Cancer. 2018 Oct;124:255-259. doi: 10.1016/j.lungcan.2018.08.015. Epub 2018 Aug 19.

PMID:
30268470
46.

Feasibility of All-in-One Venoplasty With a Venous Cuff Using an Opened Round Ligament for the Right Lobe Graft in Living Donor Liver Transplantation.

Toshima T, Yoshizumi T, Shimokawa M, Ikegami T, Harada N, Itoh S, Mano Y, Motomura T, Soejima Y, Maehara Y.

Liver Transpl. 2019 Jan;25(1):171-175. doi: 10.1002/lt.25339. No abstract available.

PMID:
30230163
47.

Histological architectural classification determines recurrence pattern and prognosis after curative hepatectomy in patients with hepatocellular carcinoma.

Okabe H, Yoshizumi T, Yamashita YI, Imai K, Hayashi H, Nakagawa S, Itoh S, Harimoto N, Ikegami T, Uchiyama H, Beppu T, Aishima S, Shirabe K, Baba H, Maehara Y.

PLoS One. 2018 Sep 14;13(9):e0203856. doi: 10.1371/journal.pone.0203856. eCollection 2018.

48.

Serum Asunaprevir and Daclatasvir Concentrations and Outcomes in Patients with Recurrent Hepatitis C Who Have Undergone Living Donor Liver Transplantation.

Harada N, Yoshizumi T, Ikegami T, Itoh S, Furusho N, Kato M, Shimoda S, Fukuhara T, Soejima Y, Maehara Y.

Anticancer Res. 2018 Sep;38(9):5513-5520. doi: 10.21873/anticanres.12885.

PMID:
30194210
49.

Radiological Features of IDO1+/PDL1+ Lung Adenocarcinoma: A Retrospective Single-institution Study.

Takada K, Toyokawa G, Tagawa T, Shimokawa M, Kohashi K, Haro A, Osoegawa A, Oda Y, Maehara Y.

Anticancer Res. 2018 Sep;38(9):5295-5303. doi: 10.21873/anticanres.12856.

PMID:
30194181
50.

Functional prognosis of critical limb ischemia and efficacy of restoration of direct flow below the ankle.

Furuyama T, Onohara T, Yoshiga R, Yoshiya K, Matsubara Y, Inoue K, Matsuda D, Morisaki K, Matsumoto T, Maehara Y.

Vascular. 2019 Feb;27(1):38-45. doi: 10.1177/1708538118798886. Epub 2018 Sep 7.

PMID:
30193553

Supplemental Content

Loading ...
Support Center